Biofil Chemicals and Pharmaceuticals Limited (NSE: BIOFILCHEM | BSE: 524396)
Source: Biofil Chemicals and Pharmaceuticals Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Biofil Chemicals and Pharmaceuticals Limited operates as an integrated chemical manufacturer and pharmaceutical trading enterprise based in Madhya Pradesh. The company’s operational architecture spans two complementary verticals: the manufacturing of active pharmaceutical ingredients (APIs), mineral supplements, and chemical excipients, alongside the merchant trading and distribution of allopathic pharmaceutical formulations and bulk drugs.
- Ferrous Sulphate Portfolio: Manufactured across Dried, Crystal, Exsiccated, and Granular grades. Used extensively as an iron fortification active in hematinic pharmaceuticals, therapeutic supplements, animal feed premixes, and industrial chemical synthesis.
- Microcrystalline Cellulose Powder (MCCP): High-purity, depolymerized cellulose excipient utilized as a binder, diluent, and disintegrant in solid dosage tableting and capsule filling.
- Cellulose Powder (CP): Inert tableting aid, glidant, and filtration medium utilized across pharmaceutical, food processing, and specialty industrial applications.
- Mineral Salts & Reagents: Potassium Chloride, Calcium Carbonate, and Sodium Chloride processed to exact pharmaceutical and analytical standards.
📋 Quick Facts / Company Snapshot: Biofil Chemicals and Pharmaceuticals Limited (NSE: BIOFILCHEM | BSE: 524396)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Biofil Chemicals and Pharmaceuticals Limited |
| Corporate Identity Number (CIN) | L24233MP1985PLC002709 |
| ISIN | INE829A01014 |
| Stock Exchange Listing | NSE: BIOFILCHEM | BSE: 524396 |
| Founding Year | 1985 |
| Registered Office & Corporate Headquarters | B/12-B, Industrial Estate, Pologround, Indore – 452015, Madhya Pradesh, India |
| Telephone & Official IR Email | +91-731-2426700 / 2723017 | bcplcompliance@gmail.com |
| Chairman & Managing Director | Mr. Ketan Shah (DIN: 08818212) |
| Chief Financial Officer (CFO) | Mr. Pavan Singh Rajput |
| Company Secretary & Compliance Officer | Mr. Apoorv Jain (M.No: A71739 / ACS-71739) |
| Promoter Group | Shah Family & Associate Investment Entities (Scope Finance, Mid India Pharma, Cyano Finance) |
| Industry / Sector Classification | Pharmaceuticals & Industrial Chemicals (APIs, Excipients & Traded Formulations) |
| Total Workforce | 24 Permanent Employees (18 Male, 6 Female, 0 Transgender) |
| Manufacturing Plants Count | 1 Active Plant (Plot No. 8, Sector-3, Kheda Industrial Estate, Pithampur, District Dhar, Madhya Pradesh) |
| Statutory Auditors | Maheshwari & Gupta, Chartered Accountants (FRN: 006179C) |
| Secretarial Auditors | Joshi Sahay & Company, Company Secretaries (Unique Code: P2025MP322400) |
| Internal Auditors | Sethiya Khandelwal & Co., Chartered Accountants |
| Bankers | State Bank of India, IDBI Bank Limited, IDFC First Bank Limited |
| Registrar & Share Transfer Agent (RTA) | Ankit Consultancy Private Limited (Indore, Madhya Pradesh) |
🏢 The Corporate Identity: Biofil Chemicals Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Biofil Chemicals and Pharmaceuticals Limited operates as an integrated chemical manufacturer and pharmaceutical trading enterprise based in Madhya Pradesh. The company’s operational architecture spans two complementary verticals: the manufacturing of active pharmaceutical ingredients (APIs), mineral supplements, and chemical excipients, alongside the merchant trading and distribution of allopathic pharmaceutical formulations and bulk drugs. Through its core manufacturing footprint in the Pithampur industrial corridor, Biofil Chemicals converts inorganic raw inputs, such as sulfuric acid and scrap iron waste, into commercial-grade chemical salts, serving healthcare formulators, animal feed processors, and industrial blenders.
The company operates an asset-light, multi-product business model designed to balance steady-state manufacturing gross margins with volume-led pharmaceutical distribution. In addition to in-house production, Biofil provides custom chemical processing and toll manufacturing (job work) facilities for domestic pharmaceutical entities. By pairing in-house technical capabilities in chemical crystallisation and powder drying with external commercial relationships, the organization maintains market relevance across both private healthcare supply chains and government tender channels.
- Manufacturing Foundation: Large-scale processing of mineral derivatives, iron compounds, and pharmaceutical excipients compliant with Indian regulatory norms.
- Trading Distribution Engine: Merchant trading of finished pharmaceuticals, bulk drugs, and surgical consumables to optimize operating leverage.
- Contract Processing & Job Work: Conversion support and capacity sharing with mid-tier pharmaceutical companies to smooth capacity utilization.
- Asset Rationalization Focus: Strategic consolidation of production at Pithampur, divesting redundant urban undertakings to extinguish liabilities and self-fund technical modernization.
The Founders, Promoters & Their Legacy
Biofil Chemicals was established by the Shah family, an entrepreneurial industrial group based in central India with decades of exposure to pharmaceutical chemical manufacturing, financial services, and bulk trading. The promoters have steered the enterprise through various macroeconomic cycles, shifting industry standards, and regulatory evolutions within the Indian bulk drug sector. Chairman and Managing Director Mr. Ketan Shah leads executive operations, overseeing strategic business planning, raw material procurement strategies, and regulatory interactions.
The wider promoter governance structure incorporates senior technical and commercial experience. Mr. Smitesh Shah, who joined the Board as a Non-Executive Non-Independent Director in August 2025, contributes 46 years of operational experience across chemical manufacturing, process scaling, and business networking in the bulk drug industry. The promoter lineage also includes Mr. Meet Shah, who contributes corporate governance oversight and operational assistance across board committees, ensuring continuity in managerial leadership.
The Journey: Corporate History & Key Milestones
Incorporated on 4th January 1985 under the Companies Act, 1956 in Madhya Pradesh, Biofil Chemicals began as a specialized chemical synthesis and formulation unit. The company broadened its ownership base through public listings on the BSE Limited and the National Stock Exchange of India Limited, establishing institutional transparency and capital access. Over four decades, the organization transitioned from basic formulation blending to the production of high-purity inorganic chemical excipients and APIs.
During the fiscal year 2025-26, the company achieved two major strategic milestones aimed at strengthening its balance sheet and modernizing operations:
- Registered Office Relocation: On 12th August 2025, the Board approved the transfer of the Registered Office from 11/12, Sector E, Sanwer Road Industrial Area, Indore, to B/12-B, Industrial Estate, Pologround, Indore – 452015, effective 1st September 2025.
- Sanwer Road Undertaking Monetization: The company completed the transfer of its plant, machinery, furniture, fixtures, and operational assets at Sanwer Road, Indore, to related party Cyano Pharma Private Limited for ₹0.21 Crores, recognizing a net profit on sale of assets of ₹2.81 Crores.
- Postal Ballot Approval for Land Rationalization: On 13th September 2025, shareholders approved a Special Resolution authorizing the sale and transfer of leasehold rights over 80,156 sq. meters of surplus unutilized industrial land at Plot No. 8, Sector-3, Kheda Industrial Estate, Pithampur, for a minimum consideration of ₹0.16 Crores, subject to final clearance from the Madhya Pradesh Industrial Development Corporation (MPIDC).
- Leadership Realignment: On 12th August 2025, Mr. Ketan Shah was elevated from Whole-Time Director to Chairman and Managing Director for a three-year term through 11th August 2028, confirmed by shareholders at the 40th AGM on 27th September 2025.
The Corporate Umbrella & Group Structure
Biofil Chemicals operates as a standalone operational corporate entity without any holding company, subsidiary, joint venture, or associate corporate entity under Section 2(87) or Section 2(6) of the Companies Act, 2013. The company forms the operational manufacturing arm of a broader promoter network centered around the Shah family, which holds ownership interests across specialized private enterprises including Cyano Pharma Private Limited, Scope Finance Company Private Limited, Mid (India) Pharmaceuticals Private Limited, and Cyano Finance and Sales Private Limited.
Operational synergies within this family group center primarily on commercial transactions with Cyano Pharma Private Limited (CPPL). CPPL operates as a pharmaceutical drug manufacturer and institutional supplier, utilizing excipients and active bulk salts produced by Biofil Chemicals as input materials, while simultaneously acting as a distribution conduit into state government tenders and institutional hospital networks.
⚙️ The Business Engine: Biofil Chemicals Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Under Indian Accounting Standard 108 (Ind AS 108), Biofil Chemicals segments its operating structure into two distinct reporting verticals: the Pharma Division and the Chemicals Division. The Pharma Division engages in the purchase and sale of traded finished goods, formulations, and active ingredients, while the Chemicals Division houses the core chemical production, mineral salt processing, and conversion facilities located at the Pithampur manufacturing plant.
During the fiscal year ended 31st March 2026, the company recorded consolidated external sales revenue of ₹0.28 Crores, reflecting a contraction of 14.99% compared to ₹0.33 Crores in FY 2024-25. This contraction was driven by a deliberate scaling back of lower-margin merchant pharmaceutical trading in favor of value-accretive in-house chemical processing. Segment profitability, capital allocation, and asset distribution across these divisions reflect this strategic shift:
| Segment Metric (₹ in Crores) | Pharma Division (FY 2025-26) | Chemicals Division (FY 2025-26) | Total FY 2025-26 | Total FY 2024-25 | Latest YoY (%) |
|---|---|---|---|---|---|
| External Sales / Revenue | 18.96 | 9.43 | 28.40 | 33.40 | -14.97% |
| % Share of Total Revenue | 66.76% | 33.20% | 100.00% | 100.00% | – |
| Raw Material / Stock Purchases | 18.77 | 7.38 | 26.15 | 31.64 | -17.35% |
| Segment Operating Expenses | 0.50 | 1.20 | 1.80 | 1.75 | +2.86% |
| Depreciation & Amortisation | – | 0.27 | 0.27 | 0.38 | -28.95% |
| Segment Results (PBIT before Other Income) | -0.31 | 0.77 | 0.37 | 0.43 | -13.95% |
| Other Income / Exceptional Gains | 2.91 | 0.17 | 3.08 | 0.31 | +893.55% |
| Segment Profit Before Tax (PBT) | 2.60 | 0.94 | 3.45 | 0.74 | +366.22% |
| Segment Assets | 21.57 | 21.26 | 42.84 | 50.96 | -15.93% |
| Segment Liabilities | 12.69 | 8.58 | 21.27 | 32.18 | -33.90% |
| Capital Expenditure (CapEx) | – | 0.20 | 0.20 | 0.10 | +100.00% |
The operational data underscores a shifting profit dynamic. While the Pharma Division represented 66.76% of operating turnover, its underlying commercial operations posted an operating segment deficit of ₹0.31 Crores (compared to a loss of ₹0.14 Crores in FY25), relying on asset sale gains to deliver a pre-tax profit of ₹2.60 Crores. Conversely, the Chemicals Division delivered an operating surplus of ₹0.08 Crores on ₹0.09 Crores of sales, demonstrating expanding manufacturing profitability as revenue rose 39.90% from ₹0.07 Crores in FY 2024-25.
The Product & Service Catalog
Biofil Chemicals maintains a technical product portfolio focused on inorganic chemical processing, tableting excipients, and bulk pharmaceuticals. The company’s core synthesized and processed product portfolio includes:
- Ferrous Sulphate Portfolio: Manufactured across Dried, Crystal, Exsiccated, and Granular grades. Used extensively as an iron fortification active in hematinic pharmaceuticals, therapeutic supplements, animal feed premixes, and industrial chemical synthesis.
- Microcrystalline Cellulose Powder (MCCP): High-purity, depolymerized cellulose excipient utilized as a binder, diluent, and disintegrant in solid dosage tableting and capsule filling.
- Cellulose Powder (CP): Inert tableting aid, glidant, and filtration medium utilized across pharmaceutical, food processing, and specialty industrial applications.
- Mineral Salts & Reagents: Potassium Chloride, Calcium Carbonate, and Sodium Chloride processed to exact pharmaceutical and analytical standards.
- Bulk Active Ingredients & APIs: Chemical manufacturing and merchant sourcing of Diclofenac Sodium, Aceclofenac, Mefenamic Acid, and Fenbendazole for human analgesics and veterinary anthelmintic medications.
- Custom Toll Manufacturing: Providing specialized batch crystallization, drying, grading, and pulverizing services for third-party formulation entities.
The Names You Know: Key Brands & Flagship Portfolio
The company markets its products primarily in B2B bulk containers, drums, and multi-wall bags directly to industrial formulators, veterinary medicine blenders, and institutional repackagers. Its product lines are positioned across distinct market segments:
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Ferrous Sulphate (Crystal / Exsiccated) | Chemicals Division / Active Mineral Salt | Pharmaceutical formulation companies producing iron hematinic tablets, syrups, and therapeutic animal nutritional feeds. |
| Microcrystalline Cellulose Powder (MCCP) | Chemicals Division / Tableting Excipients | Solid-dosage tablet manufacturers seeking compressible binders, direct-compression excipients, and disintegrants. |
| Cellulose Powder (Pure Grade) | Chemicals Division / Industrial Excipient | Pharmaceutical blenders and industrial specialty chemical manufacturers requiring inert fillers and filtration media. |
| Analgesic & Anti-Inflammatory APIs | Pharma Division / Active Bulk Drugs | Healthcare manufacturers producing human formulations containing Diclofenac Sodium, Aceclofenac, and Mefenamic Acid. |
| Fenbendazole Bulk Active | Pharma Division / Veterinary API | Veterinary drug processors and agricultural pharmaceutical companies manufacturing anthelmintic animal healthcare treatments. |
Mapping the Domestic Reach
The company’s commercial revenue is generated entirely within the Indian domestic market. The company recorded zero export revenues and zero foreign currency earnings during the financial years ended 31st March 2026 and 31st March 2025. Similarly, raw materials, process consumables, and spare parts were procured entirely from indigenous domestic vendors, with zero foreign exchange expenditure incurred across both fiscal years.
| Geographic Revenue Segment | FY 2025-26 (₹ in Crores) | FY 2025-26 (% Share) | FY 2024-25 (₹ in Crores) | FY 2024-25 (% Share) | Latest YoY (%) |
|---|---|---|---|---|---|
| Domestic Market (India) | 28.40 | 100.00% | 33.40 | 100.00% | -14.97% |
| International / Exports | 0.00 | 0.00% | 0.00 | 0.00% | N/M |
| Total Operating Revenue | 28.40 | 100.00% | 33.40 | 100.00% | -14.97% |
The Brick & Mortar Footprint: Manufacturing Plants & Offices
Biofil Chemicals has focused its physical infrastructure within the central Indian pharmaceutical manufacturing hub of Madhya Pradesh:
- Pithampur Manufacturing Facility: Located at Plot No. 8, Sector-3, Kheda Industrial Estate, Pithampur, District Dhar, Madhya Pradesh. The site holds leasehold rights over 1,06,875 sq. meters of industrial land allotted by the Madhya Pradesh Industrial Development Corporation (MPIDC). The operating chemical plant occupies approximately 26,719 sq. meters, housing chemical synthesis vessels, crystallisation bays, industrial dryers, pulverizers, and quality assurance testing laboratories.
- Pithampur Vacant Industrial Land (Under Disposal): An unutilized surplus portion measuring approximately 80,156 sq. meters at the Pithampur site, earmarked for disposal to unlock liquidity for facility modernization.
- Corporate Headquarters & Registered Office: Situated at B/12-B, Industrial Estate, Pologround, Indore – 452015, Madhya Pradesh. This facility manages corporate administration, executive decision-making, finance, secretarial governance, and commercial logistics.
- Former Sanwer Road Unit (Divested): Undertaking situated at 11/12, Sector E, Sanwer Road Industrial Area, Indore, Madhya Pradesh. The plant, machinery, fixtures, and operational tools were disposed of during FY 2025-26 to consolidate manufacturing at Pithampur.
📊 The Financial Health: Biofil Chemicals Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
The multi-year financial trajectory of Biofil Chemicals illustrates the company’s shift toward balance sheet deleveraging, asset optimization, and improved operational efficiency:
| Financial Metric | FY 2025-26 | FY 2024-25 | FY 2023-24 | Latest YoY (%) |
|---|---|---|---|---|
| Revenue from Operations | 28.40 | 33.40 | 38.90 | -14.97% |
| Other Income | 3.08 | 0.31 | 0.25 | +893.55% |
| Total Income | 31.48 | 33.71 | 39.15 | -6.62% |
| Profit Before Tax (PBT) | 3.45 | 0.74 | 0.62 | +366.22% |
| Profit After Tax (PAT) | 2.79 | 0.56 | 0.48 | +398.21% |
| Total Comprehensive Income | 2.78 | 0.58 | 0.48 | +379.31% |
| Paid-up Equity Share Capital | 16.27 | 16.27 | 16.27 | 0.00% |
| Total Equity / Net Worth | 21.56 | 18.78 | 18.20 | +14.80% |
| Basic & Diluted EPS (₹) | 1.71 | 0.34 | 0.30 | +402.94% |
Earnings, Expenses, & Take-Home Profits (Statement of Profit & Loss)
The Statement of Profit and Loss reflects how the company’s asset rationalization impacted net earnings. Total income reached ₹0.31 Crores in FY 2025-26 compared to ₹0.34 Crores in FY 2024-25. While operational turnover contracted by 14.99% as trading volumes normalized, Profit Before Tax expanded by 368.63% to ₹3.45 Crores, driven by ₹2.81 Crores in gains realized from the monetization of plant and machinery at the Sanwer Road site.
| Statement of Profit and Loss (Ind AS) | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 28.40 | 33.40 | -14.97% |
| Other Income | 3.08 | 0.31 | +893.55% |
| Total Income | 31.48 | 33.71 | -6.62% |
| Cost of Materials Consumed | 7.38 | 5.31 | +38.98% |
| Purchases of Stock-in-Trade | 18.77 | 26.32 | -28.69% |
| Changes in Inventories of Finished Goods & Traded Stock | -0.19 | -0.79 | -75.95% |
| Employee Benefits Expense | 0.80 | 0.79 | +1.27% |
| Finance Costs | 0.01 | 0.04 | -75.00% |
| Depreciation and Amortisation Expenses | 0.27 | 0.38 | -28.95% |
| Other Expenses | 0.99 | 0.92 | +7.61% |
| Total Expenses | 28.03 | 32.97 | -14.98% |
| Profit Before Exceptional Items & Tax | 3.45 | 0.74 | +366.22% |
| Profit Before Tax | 3.45 | 0.74 | +366.22% |
| Current Tax Expense | 0.41 | 0.21 | +95.24% |
| Deferred Tax Expense / (Credit) | 0.26 | -0.03 | N/M |
| Adjustment of Tax Relating to Earlier Periods | -0.01 | -0.00 | N/M |
| Total Tax Expense | 0.66 | 0.18 | +266.67% |
| Profit for the Period (PAT) | 2.79 | 0.56 | +398.21% |
| Other Comprehensive Income: Re-measurement of Defined Benefit Plans (Net of Tax) | -0.00 | 0.02 | -100.00% |
| Total Comprehensive Income for the Year | 2.78 | 0.58 | +379.31% |
Operating expenditure dropped 14.98% from ₹0.33 Crores to ₹2.80 Crores in FY 2025-26, driven by a reduction in finished goods purchases from ₹0.26 Crores to ₹0.19 Crores. Conversely, raw material consumption expanded from ₹0.05 Crores to ₹0.07 Crores, underscoring increased in-house manufacturing throughput. Depreciation charges fell from ₹0.38 Crores to ₹0.27 Crores following the derecognition of equipment at the Sanwer Road site.
Assets, Borrowings, & Net Worth (Balance Sheet)
Biofil Chemicals maintained a clean financial structure as of 31st March 2026, marked by a reduction in working capital liabilities and an expansion in liquid cash reserves. Total assets stood at ₹0.43 Crores, funded primarily by ₹0.22 Crores in Total Equity and ₹0.21 Crores in Current Liabilities, alongside ₹0.59 Crores in Non-Current Deferred Tax Liabilities.
| Balance Sheet Line Item (Ind AS) | As at 31st March 2026 (₹ in Crores) | As at 31st March 2025 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Non-Current Assets | |||
| Property, Plant and Equipment | 6.94 | 8.34 | -16.79% |
| Other Non-Current Assets | 0.05 | 0.06 | -16.67% |
| Total Non-Current Assets | 6.99 | 8.41 | -16.88% |
| Current Assets | |||
| Inventories | 4.00 | 3.34 | +19.76% |
| Trade Receivables | 27.59 | 38.32 | -28.00% |
| Cash and Cash Equivalents | 3.33 | 0.26 | +1180.77% |
| Other Current Assets | 0.95 | 0.64 | +48.44% |
| Total Current Assets | 35.86 | 42.55 | -15.72% |
| TOTAL ASSETS | 42.85 | 50.96 | -15.91% |
| Equity | |||
| Equity Share Capital | 16.27 | 16.27 | 0.00% |
| Other Equity | 5.29 | 2.51 | +110.76% |
| Total Equity / Net Worth | 21.56 | 18.78 | +14.80% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities (Net) | 0.59 | 0.33 | +78.79% |
| Total Non-Current Liabilities | 0.59 | 0.33 | +78.79% |
| Current Liabilities | |||
| Current Borrowings (Inter-Corporate Deposits) | 3.02 | 0.47 | +542.55% |
| Trade Payables (Non-MSME Creditors) | 17.06 | 30.99 | -44.95% |
| Other Financial Liabilities | 0.20 | 0.18 | +11.11% |
| Current Provisions | 0.41 | 0.21 | +95.24% |
| Total Current Liabilities | 20.69 | 31.85 | -35.04% |
| Total Liabilities | 21.28 | 32.18 | -33.87% |
| TOTAL EQUITY AND LIABILITIES | 42.85 | 50.96 | -15.91% |
A closer look at the balance sheet reveals significant working capital compression. Trade payables fell by 44.95% from ₹0.31 Crores to ₹0.17 Crores as management settled operational supplier obligations. In parallel, trade receivables were brought down from ₹0.38 Crores to ₹2.76 Crores, releasing cash into liquid bank balances, which climbed from ₹0.26 Crores to ₹0.33 Crores by year-end.
Working Capital Cycle & Schedule III Statutory Ratio Explanations
The company maintains a significant working capital footprint, driven by seasonal credit arrangements in the pharmaceutical distribution sector and batch manufacturing cycles for chemical salts. Management’s statutory Schedule III ratio analysis provides context on these operating metrics:
| Statutory Ratio | FY 2025-26 | FY 2024-25 | YoY Variance (%) | Management Explanation for Variances >25% |
|---|---|---|---|---|
| Current Ratio | 1.73 | 1.34 | +29.73% | Expansion in liquid current assets relative to current liabilities due to operational cash generation and receivables recovery. |
| Debt-Equity Ratio | 0.14 | 0.03 | +458.09% | Increase in short-term unsecured inter-corporate deposits from ₹0.47 Crores to ₹3.02 Crores to meet operating bridge requirements. |
| Debt Service Coverage Ratio (DSCR) | 337.60 | 26.94 | +1,152.95% | Substantial expansion in earnings available for debt servicing driven by non-operating gains on asset sales. |
| Return on Equity (ROE) | 13.81% | 3.02% | +357.91% | Substantial expansion in net profit after tax from ₹0.56 Crores to ₹2.79 Crores. |
| Inventory Turnover Ratio | 7.07 | 10.47 | -32.46% | Increase in cost of goods sold base alongside higher chemical manufacturing inventory buffers. |
| Trade Receivables Turnover | 0.86 | 0.94 | -7.97% | No major variance; receivables collected in line with extended industry credit cycles. |
| Trade Payables Turnover | 1.09 | 1.08 | +0.73% | Stable turnover performance; creditor clearance tracking settlement terms. |
| Net Capital Turnover Ratio | 1.87 | 3.12 | -40.02% | Lower net sales base combined with an expanded working capital asset base. |
| Net Profit Margin (%) | 2.79 | 1.67% | +487.62% | Sharp expansion in net profit after tax following the realization of asset sale proceeds. |
| Return on Capital Employed (ROCE) | 15.45% | 4.00% | +286.05% | Earnings Before Interest and Taxes (EBIT) increased significantly year-over-year. |
| Operating Profit Margin (%) | 12.18% | 2.61% | +426.89% | Higher EBIT margins driven by asset monetization gains and improved chemical margins. |
Cash Flow: Tracking the Money Movement
The company’s cash flow dynamics reflect a balance between operating settlements and capital reorganization. Cash generated from operations stood at ₹0.06 Crores, but was offset by direct tax payments of ₹0.41 Crores and deferred tax movements, resulting in net cash used in operating activities of ₹0.60 Crores. However, this was counterbalanced by net investing cash inflows of ₹0.11 Crores, driven by ₹0.13 Crores in gross proceeds from property, plant, and equipment disposals.
| Cash Flow Summary Line Item (Ind AS) | FY 2025-26 (₹ in Crores) | FY 2024-25 (₹ in Crores) | Latest YoY (%) |
|---|---|---|---|
| Profit Before Tax | 3.45 | 0.74 | +366.22% |
| Operating Adjustments (Depreciation, Finance Costs & Non-Cash Items) | 0.28 | 0.43 | -34.88% |
| Working Capital Adjustments (Receivables, Inventory & Payables) | -3.67 | -2.92 | +25.68% |
| Cash Generated from Operations | 0.06 | -1.75 | N/M |
| Direct Taxes Paid (Net) | -0.66 | -0.18 | +266.67% |
| Net Cash Flow from Operating Activities | -0.60 | -1.92 | -68.75% |
| Purchase of Property, Plant and Equipment (CapEx) | -0.20 | -0.10 | +100.00% |
| Proceeds from Sale of Property, Plant and Equipment | 1.34 | 0.00 | N/M |
| Net Cash Flow from / (Used in) Investing Activities | 1.14 | -0.10 | N/M |
| Net Proceeds / (Repayment) of Short-Term Borrowings | 2.55 | 0.03 | +8400.00% |
| Finance Costs Paid | -0.01 | -0.04 | -75.00% |
| Net Cash Flow from / (Used in) Financing Activities | 2.54 | -0.00 | N/M |
| Net Increase / (Decrease) in Cash & Cash Equivalents | 3.07 | -2.03 | N/M |
| Cash and Cash Equivalents at Beginning of Year | 0.26 | 2.28 | -88.60% |
| Cash and Cash Equivalents at End of Year | 3.33 | 0.26 | +1180.77% |
Financing activities contributed ₹2.54 Crores, reflecting short-term unsecured inter-corporate deposits mobilized to support operational liquidity during the transition of manufacturing activities to Pithampur. Closing cash and bank balances increased to ₹0.33 Crores, providing the company with an operational buffer heading into the next fiscal year.
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
Biofil Chemicals committed ₹0.20 Crores to capital expenditure during FY 2025-26, directed primarily toward plant, machinery, and equipment upgrades at Pithampur, compared to ₹0.10 Crores deployed in FY 2024-25. Capital work-in-progress (CWIP) stood at zero as of 31st March 2026, as capital assets acquired during the period were commissioned directly into production.
In terms of research and technology absorption, the company incurred no separate, identifiable research and development expenditure during the year, maintaining an R&D intensity of 0.00% of operational turnover. In accordance with Section 134(3)(m) of the Companies Act, 2013, the company reported zero foreign exchange earnings (exports) and zero foreign exchange outgo (imports or foreign travel), running its business entirely on domestic sourcing and regional distribution networks.
👥 Power & Control: Biofil Chemicals Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
The governance structure of Biofil Chemicals is led by a six-member Board of Directors comprising one Executive Director, two Promoter Non-Executive Non-Independent Directors, and three Non-Executive Independent Directors, including one Woman Independent Director. Key leadership details across the Board and management team include:
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Ketan Shah | Chairman & Managing Director | 08818212 | Promoter / Executive Director |
| Mr. Meet Shah | Non-Executive Non-Independent Director | 06578351 | Promoter / Non-Executive Non-Independent |
| Mr. Smitesh Shah | Non-Executive Non-Independent Director | 00326182 | Promoter / Non-Executive Non-Independent |
| Mr. Ashok Kumar Ramawat | Non-Executive Independent Director | 08818263 | Independent / Non-Executive |
| Mr. Satish Beohar | Non-Executive Independent Director | 09220291 | Independent / Non-Executive |
| Mrs. Gayatri Padiyar | Non-Executive Woman Independent Director | 10260173 | Independent / Non-Executive Woman Director |
| Mr. Pavan Singh Rajput | Chief Financial Officer (CFO) | Not Applicable | Key Managerial Personnel |
| Mr. Apoorv Jain | Company Secretary & Compliance Officer | Not Applicable | Key Managerial Personnel (Appointed 19.04.2025) |
Board committee leadership is held entirely by Independent Directors. Mrs. Gayatri Padiyar serves as Chairperson of the Audit Committee, the Nomination & Remuneration Committee, and the Stakeholders’ Relationship Committee, supported by fellow Independent Directors Mr. Ashok Kumar Ramawat and Mr. Satish Beohar. The Finance Committee, constituted on 12th August 2025, comprises Chairman and Managing Director Mr. Ketan Shah and Non-Executive Director Mr. Meet Shah.
Who Owns the Stock? Shareholding Pattern
The share capital of Biofil Chemicals stands at ₹0.16 Crores, divided into 1,62,73,800 fully paid equity shares with a par value of ₹10/- each. The shareholding structure as of 31st March 2026 is distributed across the following ownership categories:
| Shareholder Category | Number of Shares Held | % Share of Total Issued Shares |
|---|---|---|
| Promoter & Promoter Group | 73,90,550 | 45.41% |
| Institutional Investors (FPIs / MFs / Banks / FIs) | 0 | 0.00% |
| Public / Non-Institutional Shareholders | 88,83,250 | 54.59% |
| Total Issued Equity Capital | 1,62,73,800 | 100.00% |
Within the promoter base, corporate investment entities hold significant stakes, led by Scope Finance Company Private Limited with 22,62,500 shares (13.90%), Mid (India) Pharmaceuticals Private Limited with 11,75,250 shares (7.22%), and Cyano Finance and Sales Private Limited holding 8,76,450 shares (5.39%). Individual family holdings include Meena Shah with 6,60,312 shares (4.06%), Niyati Shah with 6,59,312 shares (4.05%), Ketan Shah with 4,93,062 shares (3.03%), Sandeep Shah with 4,23,812 shares (2.60%), Romil Shah with 3,82,550 shares (2.35%), and Smitesh Shah holding 1,86,662 shares (1.15%). In the non-promoter public category, Starline Equifin Private Limited holds 12,21,368 shares, representing a 7.51% equity interest.
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
Biofil Chemicals does not hold shares in any subsidiary, joint venture, or associate corporate entity. Consequently, disclosures under Section 129(3) of the Companies Act, 2013 in Form AOC-1 are not applicable.
| Entity Name | Relationship | Country | % Equity Shareholding | Operating Turnover (₹ in Crores) | Profit / (Loss) After Tax (₹ in Crores) |
|---|---|---|---|---|---|
| No subsidiaries, joint ventures, or associate companies exist. The company operates as a standalone corporate entity. | |||||
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
The company held zero non-current financial investments or mutual fund treasury placements as of 31st March 2026. Banking relationships are maintained with a consortium comprising State Bank of India, IDBI Bank Limited, and IDFC First Bank Limited. The company carries no long-term bank borrowings; current borrowings consist of ₹3.02 Crores in unsecured inter-corporate deposits. During the fiscal year, no credit ratings were assigned or outstanding, as credit rating requirements were not applicable to its debt profile.
Off-balance-sheet commitments and contingent matters are managed conservatively:
- Vacant Land Writ Petition: The company is party to a pending writ petition filed in 2012 before the Hon’ble High Court of Madhya Pradesh (Bench at Indore) against the Madhya Pradesh Audyogik Kendra Vikas Nigam (Indore) Limited (MPAKVN, now MPIDC) and other parties regarding vacant industrial land measuring 94,462 sq. meters at Kheda Industrial Area, Pithampur. Legal counsel has advised that this matter is remote and will not result in financial liability.
- Taxation Disputes & Guarantees: The company reports zero disputed dues in respect of Income Tax, Goods and Services Tax, Customs Duty, or Excise Duty. There are no corporate guarantees or letters of comfort issued on behalf of third parties.
- Capital Commitments: The company had zero estimated amounts of contracts remaining to be executed on capital account (net of advances) as of 31st March 2026.
- Regulatory Penalties & SAT Appeal: During FY 2025-26, BSE and NSE levied SOP fines of ₹0.36 Crores each (totaling ₹0.07 Crores) regarding Board composition compliance under Regulation 17(1)(c). The company paid these penalties under protest and has filed an appeal before the Securities Appellate Tribunal (SAT), which remains pending. A minor fine of ₹0.03 Crores each was also paid to BSE and NSE for a 34-day vacancy in the Company Secretary role, which was resolved on 19th April 2025.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Biofil Chemicals has built competitive positions across specific pharmaceutical and chemical niches:
- Inorganic Salt Synthesis Infrastructure: The Pithampur facility possesses specialized infrastructure for processing acidic mineral by-products into high-purity iron compounds and excipients. This chemical synthesis capability creates technical barriers to entry for standard formulation repackagers.
- Integrated Excipient Production: By producing binders and disintegrants such as Microcrystalline Cellulose Powder (MCCP) and pure Cellulose Powder alongside active bulk minerals, Biofil offers an integrated chemical basket to solid-dosage pharmaceutical manufacturers.
- Direct Distribution Conduits: Long-standing supplier relationships and commercial arrangements with entities like Cyano Pharma Private Limited provide steady demand for raw materials and finished goods channeled into public healthcare programs.
- Consolidated, Low-Cost Operational Footprint: Operating an unencumbered production campus at Pithampur keeps fixed overhead low, allowing the business to maintain commercial viability in competitive markets.
What Could Go Wrong? Key Challenges & Business Risks
The company operates in a challenging operating environment characterized by specific industrial and commercial risks:
- High Customer Concentration & Related-Party Reliance: A significant portion of revenue and raw material sourcing depends on transactions with related parties, including Cyano Pharma Private Limited, which accounted for ₹2.41 Crores in sales and ₹0.63 Crores in purchases in FY 2025-26. Any shifts in commercial terms could impact top-line stability.
- Input Cost Volatility: Basic production relies heavily on volatile bulk commodities, including sulfuric acid and iron scrap. Sharp swings in chemical market prices directly affect gross manufacturing margins.
- Regulatory & Land Monetization Delays: The proposed modernization plan depends on unlocking at least ₹0.16 Crores from the transfer of surplus leasehold land at Pithampur. This disposal remains contingent on statutory clearances from MPIDC and resolving related land litigations.
- Working Capital Intensity: With trade receivables of ₹2.76 Crores relative to operating turnover of ₹0.28 Crores, the business carries extended collection cycles, making liquidity management critical.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Management’s strategic roadmap focuses on technical modernization and margin enhancement. The planned modernization of the Pithampur site will introduce dedicated manufacturing lines for hormonal preparations, direct-compression grade granules, and high-margin tablet blends. This technical expansion will allow Biofil to transition from low-margin bulk chemicals to specialized pharmaceutical components.
To fund these initiatives without excessive debt, the company plans to utilize the anticipated minimum ₹0.16 Crores in net proceeds from its surplus Pithampur land parcel. The capital will be deployed to clear outstanding leasehold charges, upgrade facilities to current Good Manufacturing Practices (cGMP), install modern processing equipment, and expand working capital support for expanded production.
The Verdict: Strategic Outlook & Conclusion
Biofil Chemicals and Pharmaceuticals Limited stands at an operational turning point. The consolidation of manufacturing operations at Pithampur, the successful divestment of the Sanwer Road unit, and the monetization of surplus real estate provide a roadmap to modernizing its production base. While near-term performance remains tied to domestic chemical pricing, related-party trading volumes, and administrative land clearances, the company’s unencumbered balance sheet and focus on specialized tablet excipients and hormonal preparations offer a path toward higher-margin, specialized chemical manufacturing.
Frequently Asked Questions (FAQs) About Biofil Chemicals
Q1: What does Biofil Chemicals manufacture and what are its core products?
Biofil Chemicals manufactures active mineral salts, pharmaceutical excipients, and bulk ingredients, specializing in Dried, Crystal, and Exsiccated Ferrous Sulphate, Microcrystalline Cellulose Powder (MCCP), and pure Cellulose Powder. It also trades active pharmaceutical ingredients (APIs), including Diclofenac Sodium and Fenbendazole, alongside finished pharmaceutical formulations.
Q2: What were Biofil Chemicals’ revenue and net profit figures in FY 2025-26?
In FY 2025-26, the company generated Revenue from Operations of ₹0.28 Crores and Total Income of ₹0.31 Crores. Profit After Tax (PAT) stood at ₹2.79 Crores, an increase of 399.50% compared to ₹0.56 Crores in FY 2024-25, supported by ₹2.81 Crores in gains realized from the sale of plant assets at its Sanwer Road unit.
Q3: Who manages and controls Biofil Chemicals?
The company is led by the Shah family. Mr. Ketan Shah serves as Chairman and Managing Director, alongside Promoter Non-Executive Directors Mr. Meet Shah and Mr. Smitesh Shah. The promoter group owns 45.41% of total equity share capital, with the remaining 54.59% held by public and non-institutional shareholders.
Q4: Where are the company’s manufacturing facilities located and what is its export footprint?
The company operates an active manufacturing plant located at Plot No. 8, Sector-3, Kheda Industrial Estate, Pithampur, District Dhar, Madhya Pradesh. The company currently exports zero products, generating 100% of its operating revenue within the Indian domestic market using domestically sourced raw materials.
Q5: What is the debt profile and net worth of Biofil Chemicals?
As of 31st March 2026, Biofil Chemicals carries zero long-term bank debt. Its borrowings consist of ₹3.02 Crores in short-term unsecured inter-corporate deposits. Total Equity (Net Worth) stood at ₹0.22 Crores, supported by a healthy current ratio of 1.73 and liquid cash and bank balances of ₹0.33 Crores.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.biofilgroup.net